Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone Induction for Fetal Demise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Intrauterine fetal death as confirmed by absence of cardiac motion on ultrasound by Attending physician at the time of admission to the hospital.~2. Estimated gestational age greater than 20 weeks~3. Hemodynamically stable and appropriate for induction of labor as per primary clinical health team in house~4. Women with one prior low transverse cesarean delivery~Exclusion Criteria:~1. History of 2 or more low transverse cesarean deliveries~2. Prior classical cesarean delivery~3. History of abdominal myomectomy~4. Known or suspected allergic reaction to mifepristone~5. Known or suspected adrenal gland disease~6. Known or suspected bleeding diatheses or coagulopathies~7. Known or suspected use of QTc-prolonging medication~8. Known maternal medical or physical conditions that prohibits vaginal delivery

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- mifepristone (Type: ACTIVE_COMPARATOR): following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery
- placebo pill (Type: PLACEBO_COMPARATOR): following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).